Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 5 (a) A comparison of the effects of activator protein-1 (AP-1) consensus (AP-1 cons) and AP-1 mutant (AP-1 mut) decoy oligodeoxynucleotide (dODN) on neointimal area eight weeks after percutaneous transluminal coronary angioplasty (PTCA). (b) A lack of effect of C/EBP consensus (C/EBP cons) and C/EBP mutant (C/EBP mut) dODN on neointimal area four weeks after PTCA (see Fig. 4a for comparison).
|
